Abstracts tagged "Biologics"

Abstract Number: 1416 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Golimumab In Chinese Patients With Active Rheumatoid Arthritis Despite MTX Therapy: Results From a Randomized, Placebo-Controlled, Phase 3 Trial
Zhanguo Li¹, Fengchun Zhang², Jonathan Kay³, Kaiyin Fei⁴, Chenglong Han⁵, Yanli Zhuang⁴, Zhong Wu⁴ and Elizabeth C. Hsia⁴, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Janssen Global Services, LLC., Malvern, PA
Background/Purpose: Assess safety and efficacy of GLM+MTX over 1yr in a multicenter, randomized, placebo (PBO)-controlled study of Chinese pts with active RA despite MTX therapy.…
Abstract Number: 479 • 2013 ACR/ARHP Annual Meeting
Attainment Of Remission, Functional, and Quality Of Life Improvements With Golimumab Treatment In Rheumatoid Arthritis Are Associated With Patient Expectations
B Dasgupta¹, B Combe², I Louw³, J Wollenhaupt⁴, C Zerbini⁵, A Beaulieu⁶, H Schulze-Koops⁷, P Durez⁸, V Wolff⁹, R Yao¹⁰, HH Weng¹⁰, M Govoni¹¹ and N Vastesaeger¹², ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Lapeyronie, Montpellier, France, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Schön-Klinik, Hamburg, Germany, ⁵Hospital Heliópolis, Serviço de Reumatologia, São Paulo, Brazil, ⁶Centre de Rhumatologie, St-Louis, QC, Canada, ⁷University of Munich, Munich, Germany, ⁸Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁹Hospital del Salvador, Santiago, Chile, ¹⁰Merck & Co., Inc., Whitehouse Station, NJ, ¹¹MSD Italy, Rome, Italy, ¹²Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Golimumab (GLM) and other tumor necrosis factor antagonists are used as add-on therapy for patients with rheumatoid arthritis (RA) who have not responded to…
Abstract Number: L11 • 2012 ACR/ARHP Annual Meeting
First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial
Frank Behrens¹, Mikkel Ostergaard², Rumen Stoilov³, Piotr Wiland⁴, Thomas W. Huizinga⁵, Vadym Y. Berenfus⁶, Paul-Peter Tak⁷, Stoyanka Vladeva⁸, Juergen Rech⁹, Andrea Rubbert-Roth¹⁰, Mariusz Korkosz¹¹, Dmitriy Rekalov¹², Igor A. Zupanets¹³, Bo J. Ejbjerg¹⁴, Jens Geiseler¹⁵, Julia Fresenius¹⁵, Roman P. Korolkiewicz¹⁶, Arndt J. Schottelius¹⁶ and Harald Burkhardt¹, ¹CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Germany, ²Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ³Clinic of rheumatology, University Hospital (MHAT) St. Ivan Rilski, Sofia, Bulgaria, ⁴Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Occupational Diseases, Regional Clinical Hospital, Donetsk, Ukraine, ⁷Academic Medical Center / currently also GlaxoSmithKline, Amsterdam, Netherlands, ⁸Second Internal Clinic UMHAT Stara Zagora, Stara Zagora, Bulgaria, ⁹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ¹⁰Internal Medicine I, University of Cologne, Cologne, Germany, ¹¹Malopolskie Centrum Medyczne, Krakow, Poland, ¹²Department of Internal Diseases, Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, ¹³Clinical and Diagnostics Centre of National Pharmaceutical University MOH of Ukraine, Kharkiv, Ukraine, ¹⁴Slagelse Sygehus, Slagelse, Denmark, ¹⁵Asklepios Clinic Munich-Gauting, Gauting, Germany, ¹⁶Development, MorphoSys AG, Martinsried/Planegg, Germany
Background/Purpose: MOR103, a human mAb targeting GM-CSF, is being evaluated for treatment of rheumatoid arthritis (RA). Pre-clinical studies on cytokine function and investigations in experimental…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].